Blog

Nelson Advisors has been featured in 'Hims &amp; Hers’ USD 1.15bn Eucalyptus deal signals new era for Australia’s digital health' – Dealspeak APAC.Source: <a href="https://ionanalytics.com/insights/mergermarket/hims-hers-usd-1-15bn-eucalyptus-deal-signals-new-era-for-australias-digital-health-dealspeak-apac/">https://ionanalytics.com/insights/mergermarket/hims-hers-usd-1-15bn-eucalyptus-deal-signals-new-era-for-australias-digital-health-dealspeak-apac/</a>US telehealth giant Hims &amp; Hers’ USD 1.15bn acquisition in February of Australian digital health company Eucalyptus is expected to significantly shake up the international digital health sector. The deal, set to close in mid 2026, has certainly caused a stir in Australia, where it is by far the largest acquisition of a preventative healthcare company.Pinning down precise transaction multiples is difficult given the deal’s limited valuation disclosure. But the “up to USD 1.15bn” consideration, which was based on a run‑rate derived from January 2026 revenue, and triple‑digit, year-over-year, quarterly ARR growth through 2025, implies a mid‑ to high‑single‑digit historic revenue multiple and a sizeable payday for Eucalyptus’ founder Tim Doyle and his private equity backers.This multiple is at the upper end of prevailing sector benchmarks. Nelson Advisors’ January 2026 HealthTech valuation report puts general digital health assets at 4x-6x revenue. But the report notes that premium telehealth and AI‑enabled platforms – those showing strong growth and embedded workflows – command 6x-8x+ revenue multiples.The deal valuation will have caught the attention of other players and investors in Australia’s burgeoning preventative medicine sector, which is already well known for its strong foundation in biotech, innovative digitally-driven health and AI-powered diagnostics.Sector stakeholders will also have noted the wider implications of the Eucalyptus deal, which Nelson Advisors said has turned Hims &amp; Hers into an international “powerhouse” and “represents one of the most significant consolidations in the history of the [global] telehealth industry”.

Nelson Advisors featured in Mergermarket's Dealspeak APAC

The European HealthTech landscape this week reflects a major shift away from casual consumer "wellness" apps and a deep pivot toward clinical deep-tech, workflow automation, and massive regulatory lobbying.Here are the standout developments and funding rounds dominating the industry right now:1. The Heavyweight Funding DealsThe market is favouring high-conviction, late-stage bets alongside specialised clinical devices:Neko Health’s Massive Move: Swedish preventative health startup Neko Health (co-founded by Spotify’s Daniel Ek) secured a $700M Series C round. The company revealed it has reached 100,000 members and achieved profitability at the individual clinic level, continuing its massive expansion of AI-driven full-body scans across Europe.CurifyLabs: Finnish personalized medicine startup CurifyLabs bagged €12M in Series A funding to further automate and scale its tailored drug manufacturing technology.Respiro Diagnostics: The UK lung-health startup closed a £1M round to advance its innovative breath-based diagnostics for respiratory diseases.2. Shift to Deep-Tech &amp; Cross-Border Data InteroperabilityEuropean venture capital and government backing are aggressively targeting core clinical issues:Azalea Vision Eyes Clinical Trials: Belgian healthtech firm Azalea Vision secured up to €7.5 million in EIC (European Innovation Council) Accelerator funding. The capital is designated to move their medical-grade smart contact lens, which functions as a non-invasive biosensing platform to track biomarkers via tears, into formal clinical trials.Dismantling Regional Data Silos: The EIC announced the first three winners of its health data interoperability initiative, deploying €3.78 million. Moving past small-scale pilots, projects like CARDIO-HUB (elderly remote heart monitoring) are being fully deployed to allow seamless cross-border medical data sharing.3. Regulatory Frictions: The "MDR vs. AI Act" ClashStartups and regulatory bodies are tackling the administrative bottlenecks of dual compliance:The Overlap Lobby: European healthtech developers are experiencing massive friction navigating the simultaneous compliance demands of the EU AI Act and the stringent Medical Device Regulations (MDR).Industry groups are actively lobbying the European Commission to streamline these overlapping boundaries, with EU Parliament projections estimating that harmonisation could save the ecosystem up to €3.3 billion annually in administrative bloat.The UK's Fast-Track Pivot: Seizing on the mainland's regulatory logjam, the UK's MHRA has progressed its draft Medical Devices Regulations. This establishes an "International Reliance" pathway, allowing tech manufacturers with existing approvals from trusted global regulators to bypass standard British red tape and fast-track into the UK healthcare market.4. Clinician Burnout Is Driving Software AdoptionAccording to recent data from the Philips Future Health Index, roughly 65% of European clinicians have actively ramped up their daily use of AI medical tech. Because healthcare workers are desperate to claw back time from administrative tasks, VC funding is highly concentrated on operational "plumbing", such as AI surgical infrastructure, automated clinical documentation, and scheduling platforms—rather than patient-facing apps.&gt;&gt;&gt;&gt;The European MedTech and medical device landscape is undergoing a massive, structural recalibration. The speculative "wellness app" era has completely evaporated, replaced by a heavy focus on clinical deep-tech, major regulatory overhauls, and structural legal changes.The major shifts and updates defining European MedTech include:1. The Legal Reality: The "AI Act Omnibus" &amp; MDR CollisionThe biggest structural news for device manufacturers centres on a massive breakthrough regarding how medical AI will be governed in Europe.No Duplicate Audits: Following fierce lobbying from industry group MedTech Europe over the "double-regulation" nightmare, EU co-legislators have finalised the "AI Act Omnibus" framework. It dramatically reduces duplication, meaning AI-driven medical devices will not have to undergo two completely separate compliance pathways under both the AI Act and the Medical Device Regulation (MDR/IVDR). Instead, the AI Act's high-risk safety, data quality, and cybersecurity requirements will be integrated directly into the existing MDR/IVDR framework.August 2028 Extension: Manufacturers of high-risk AI medical devices have officially been granted a major breathing-room extension to August 2028 to fully comply with high-risk obligations.The Immediate August Catch: Do not wait on everything, though. Basic transparency rules—such as explicit disclosures for patient-facing AI chatbots and clear labeling of synthetic/AI-generated healthcare content, kick in next month (August 2026).2. EU Pushes Back on Notified Bodies with Strict TimelinesIn an effort to stop innovative medical devices from fleeing Europe for the US market due to approval bottlenecks, the European Commission has introduced aggressive new rules targeting Notified Bodies.Implementing Regulation (EU) 2026/977 establishes uniform, capped maximum timelines for conformity assessments. For example, Notified Bodies are now bound to stricter time limits (e.g., 30 days for application reviews, 120 days for Quality Management System audits).They must also provide fully standardised, transparent pricing quotes to manufacturers and publish their cost structures and processing duration data annually to prevent price gouging.3. Mandatory EUDAMED Data &amp; The Next Compliance WaveThe transition period for the first four fully functional modules of EUDAMED (the EU's centralised medical device database) ended recently.All manufacturers, importers, and notified bodies are now under mandatory transparency compliance for devices entering the market.New Portal Update: The European Commission announced that the playground environment for uploading crucial Summary of Safety and Clinical Performance (SSCP) data goes live this month (July 2026), ahead of the mandatory production deadline.4. The UK's Fast-Track "International Reliance" PathwayCapitalising on mainland Europe's historical regulatory friction, the UK's MHRA has progressed its draft Medical Devices Regulations. This explicitly establishes an "International Reliance" pathway. It allows hardware and Software-as-a-Medical-Device (SaMD) manufacturers who already hold approvals from trusted global bodies (like the US FDA) to bypass British red tape and fast-track directly into the UK market.5. Late-Stage Capital &amp; Deep-Tech FundingWhile early-stage seed funding remains highly selective, capital is concentrating heavily on late-stage category leaders and deep-tech clinical hardware:Alan’s Landmark Round: The French digital health and preventative insurance platform locked in a massive €480 million Series G round at a €5.5 billion valuation, making it Europe's most valuable private HealthTech entity.Clinical Smart Lenses: Belgian MedTech firm Azalea Vision secured €7.5 million via the European Innovation Council (EIC) Accelerator. The capital will fund clinical trials for their medical-grade smart contact lens, which treats complex corneal properties and acts as a non-invasive biosensor analyzing biomarkers directly via patient tears.Interoperability Infrastructure: Moving away from small regional "pilots," the EIC deployed millions to scale cross-border clinical data infrastructure, focusing heavily on connected hardware like CARDIO-HUB (remote cardiac monitoring for the elderly). The Big Takeaway: Europe is actively rewriting its MedTech playbook. The extension of the AI Act deadlines coupled with strict new efficiency rules on Notified Bodies shows Brussels is finally listening to warnings about losing its innovation edge to the US and Asia.Nelson Advisors &gt; European MedTech and HealthTech Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTlloyd@nelsonadvisors.co.ukpaul@nelsonadvisors.co.ukMeet Nelson Advisors @ 2026 EventsDigital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp;HLTH Europe &gt; June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp;World Health Summit 2026 &gt; October 2026, Berlin, GermanyHealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USABarclays Health Elevate &gt; October 2026, London, UK&nbsp;Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, GermanyVenture Capital World Summit &gt; December 2026 Toronto, Canada

This Week in European MedTech and HealthTech: 17th July 2026

The European healthcare technology and medical technology sectors have reached a major structural inflection point, transitioning from an era of venture subsidised experimentation into a phase of disciplined industrial maturity. This shift, historically characterised as the "Great Rationalisation," represents the end of the liquidity-fuelled, growth-at-all-costs environment that peaked in the early 2020s. The modern market is defined by a rigorous "flight to quality," where enterprise valuations are no longer driven by raw revenue expansion but by clinical utility, regulatory resilience, and technological defensibility. &nbsp;&nbsp; The macro capital movements within the European landscape demonstrate this selective recovery. While early-stage deal counts have contracted, capital concentration has intensified within a narrow band of validated category leaders. European digital health venture funding in the first quarter of 2026 reached approximately $1.2 Billion across 67 deals, representing a decline of 44% in capital deployed and 46% in deal count compared to the same period in 2025. However, the average deal size rose by 8% year-on-year to $21 Million, driven by late-stage mega-rounds. These transactions were led by Oviva’s $235 Million Series D, Alan’s $116 Million Series G, and DentalMonitoring’s $100 Million Series D. &nbsp; Underneath these subdued private financing volumes sits a structurally expanding end-market. The European digital health market generated an estimated $130 Billion in revenue in 2025 and is projected to compound at a 10% compound annual growth rate (CAGR) toward $314 Billion by 2034.&nbsp; &nbsp;&nbsp; Concurrently, the European HealthTech market is forecast to grow at an 18% CAGR from $97 Billion in 2025 to $222 Billion by 2030. This gap between private funding constraints and robust underlying clinical demand is the precise condition under which corporate strategics and private equity sponsors are executing consolidation plays.The Translation Gap and the Anatomy of the Founder Banker The genesis of the founder-led advisory movement lies in a fundamental inefficiency within the traditional investment banking model, often referred to as the "Translation Gap". Historically, healthcare banking and technology banking operated as distinct, hermetically sealed silos. Healthcare bankers were trained to evaluate clinical trial phases, patient registries and the slow, capital-intensive paths to regulatory clearance, but they frequently struggled with the unit economics of software scalability.&nbsp; Conversely, technology bankers evaluated assets through generalist software-as-a-service (SaaS) metrics, such as Customer Acquisition Cost (CAC), Lifetime Value (LTV), and monthly active user engagement, while remaining blind to the friction of hospital procurement, legacy Electronic Patient Record (EPR) integrations, and clinical safety standards. &nbsp;&nbsp; This Translation Gap has become a significant liability as healthcare assets have grown in technological and clinical complexity. The clinical software, surgical robotics and interoperable data stacks of the modern market exceed the analytical capabilities of generalist finance.&nbsp; To bridge this linguistic and valuation mismatch, the "Founder Banker" has emerged as a critical class of advisor. These individuals are former entrepreneurs or clinicians who have personally built, scaled, and exited healthcare technology ventures. &nbsp;&nbsp; The primary value proposition of the founder banker is rooted in operational empathy and technical fluency. Having experienced the operational friction of medical device audits, clinical trials, and NHS procurement, they can translate early-stage consumer engagement metrics into the clinical validation required by risk-averse institutional buyers. This operational pedigree allows them to de-risk complex technical assets for private equity sponsors and corporate development teams, transforming administrative hurdles into clear valuation drivers. To maintain structural clarity, market analysts must distinguish this European investment banking phenomenon from Bankers Healthcare Group (BHG). Founded in the United States in 2001 by Eric Castro, Robert Castro, and Albert Crawford, BHG is a commercial financial services firm that provides working capital, promissory notes, and point-of-sale patient lending to licensed US healthcare practitioners. Partially owned by Nashville-based Pinnacle Bank, BHG leverages a state-of-the-art loan delivery platform to manage one of the largest community bank loan networks in the United States. This practitioner-lending model is conceptually distinct from the European founder banker ecosystem, which focuses strictly on corporate finance, mid-market M&amp;A, and strategic capital raising for healthcare technology platforms.Click here to read the report in full -&nbsp;﻿<a href="https://www.healthcare.digital/single-post/the-rise-of-the-founder-banker-in-european-healthcare-technology-and-artificial-intelligence">https://www.healthcare.digital/single-post/the-rise-of-the-founder-banker-in-european-healthcare-technology-and-artificial-intelligence</a>

The Rise of the Founder Banker in European Healthcare Technology and Artificial Intelligence

Nelson Advisors has been invited to speak at the Capital XChange Programme, Global Health Exhibition 2026 which unites government officials, investors, VCs, PE firms, Healthtech/Biotech startups.Source: <a href="https://news.sky.com/story/global-health-exhibition-set-to-return-as-saudi-healthcare-market-booms-13559917">https://news.sky.com/story/global-health-exhibition-set-to-return-as-saudi-healthcare-market-booms-13559917</a>Saudi Arabia's Global Health Exhibition is set to return in October as the country strengthens its position as one of the world's fastest-growing healthcare markets.Last year's event saw the signing of over $35.5bn (£26bn) in healthcare agreements across hospital infrastructure, life sciences, digital health and international healthcare partnershipsLaunched in 2018, the exhibition has grown faster than almost any comparable event in international healthcare since then, with more than 131,000 attendees in 2025.'Reimagine the future of health'The event is being organised by Tahaluf, under the patronage of Saudi Arabia's Ministry of Health, and supports the country's Vision 2030 Health Sector Transformation Program.It was described as a place where "visionary investors, pioneering startups, and technology leaders convene to reimagine the future of health and then build it", by Saudi Arabia's minister of health.Mr Fahad bin Abdulrahman Aljalajel added that: "With one of the world's fastest-growing health markets, Saudi Arabia has emerged as the natural home for the world's fastest-growing health exhibition."Senior representatives of Eli Lily, the world's most valuable pharmaceutical company, have also praised the event.Mostafa Abdelrahman, President and General Manager of Eli Lilly Saudi Arabia, described last year's Global Health Exhibition as a "valuable opportunity" for the company.New clinical zonesTahaluf has announced that this year's event will feature three new clinical zones - a dental zone, an orthopaedics and rehabilitation zone and a dermatology and aesthetics zone.There will also be a host of new programmes and changes, including:Capital Xchange - Will introduce structured sessions on capital deployment and healthcare policy, curated site visits to Saudi facilities and research centres, and a reverse pitching format in which corporations and investors present their requirements directly to start-ups. This is designed to build on the 2025 investor track, which brought together more than 200 investors managing a combined $65bn of assets under management across 40 countries. The return of the NextGen Pitch Competition - Welcoming 54 healthcare startups and scaleups from around the world, participants will gain access to investors, healthcare leaders and strategic partners, while presenting innovations across digital health and AI, bio and life sciences and medtech. For the first time, all semi-finalists and finalists will participate in a dedicated investor networking programme designed to create direct connections with investors and decision-makers attending the event. Leaders Club 100 - A new invitation-only initiative that will connect government ministers, chief executives, and senior decision-makers through private roundtables and dedicated networking sessions. Pulse Studio podcast - A live podcast facility on the exhibition floor, which will feature one-on-one in-depth interviews with healthcare leaders, further extending the event's reach.Source: <a href="https://www.globalhealthsaudi.com/investors-and-startups/invest-in-health/">https://www.globalhealthsaudi.com/investors-and-startups/invest-in-health/</a>

Nelson Advisors invited to speak at the Capital XChange Programme, Global Health Exhibition 2026

Nelson Advisors featured in InnLifes article 'Come è nata Wise: la medtech italiana che rivoluziona il neuromonitoraggio e la neuromodulazione con elettrodi impiantabili ergonomici'Translated as 'How Wise was founded: the Italian medtech company revolutionizing neuromonitoring and neuromodulation with ergonomic implantable electrodes.'Source: <a href="https://www.innlifes.com/med-tech/la-storia-di-wise-elettrodi-per-cervello/" data-mce-href="https://www.innlifes.com/med-tech/la-storia-di-wise-elettrodi-per-cervello/">https://www.innlifes.com/med-tech/la-storia-di-wise-elettrodi-per-cervello/</a>«Siamo manifatturieri e rimarremo manifatturieri», dice Ravagnan. Wise Cortical Strip, il prodotto da cui tutto è cominciato, continua ad aprire possibilità prima impensabili per i neurochirurghi. Il salto di scala, però, arriverà da Heron e da ciò che verrà dopo. Intanto, Nelson Advisors, società di advisory finanziario con sede a Londra, annovera Wise tra le “20 Future Italian HealthTech and MedTech Leaders”."We are manufacturers, and we will remain manufacturers," says Ravagnan. The Wise Cortical Strip—the product that started it all—continues to open up possibilities for neurosurgeons that were previously unimaginable. However, the leap in scale will come from Heron and what follows it. Meanwhile, Nelson Advisors, a London-based financial advisory firm, has named Wise one of the "20 Future Italian HealthTech and MedTech Leaders."KEYPOINTSParola chiave: serendipità. Una scoperta nata per caso in laboratorio ha portato alla creazione di un materiale conduttivo, elastico e biocompatibile e alla nascita di Wise. La tecnologia proprietaria di Wise impianta nanoparticelle nel silicone per realizzare circuiti flessibili ad alta precisione. Dal confronto con i neurochirurghi del Besta di Milano è nato un elettrodo che migliora il monitoraggio cerebrale durante gli interventi. WISE Cortical Strip è oggi un dispositivo certificato in Europa, approvato negli Stati Uniti e già utilizzato nella pratica clinica. Con Heron invece Wise punta a rivoluzionare la terapia del dolore cronico con un elettrodo minimamente invasivo che si apre una volta impiantato. Wise ha chiuso un round da 30 milioni che investirà nello sviluppo di Heron, mantenendo ricerca e produzione a Cologno Monzese.

Nelson Advisors featured in InnLifes article 'Come è nata Wise: la medtech italiana che rivoluziona il neuromonitoraggio e la neuromodulazione con elettrodi impiantabili ergonomici'

The European HealthTech landscape is seeing a definitive, practical shift. The era of speculative consumer wellness apps has taken a backseat, replaced by a heavy focus on deep-tech clinical solutions, interoperability and reducing administrative burnout for healthcare staff.The major developments shaping European HealthTech include:1. Regulatory Shifts: Navigating the AI Act &amp; MDR OverlapStartups and mature HealthTech companies are currently grappling with dual compliance demands as the EU AI Act and the stringent Medical Device Regulations (MDR/IVDR) intersect.The Compliance Friction: Developers of AI-driven medical tech are facing parallel, overlapping regulatory requirements. Industry bodies are aggressively lobbying the European Commission to streamline these rules; the EU Parliament projects that cutting this administrative bloat could save the ecosystem up to €3.3 Billion annually.The UK’s "International Reliance" Play: Capitalising on mainland Europe's regulatory bottleneck, the UK’s MHRA has progressed its draft Medical Devices Regulations. This creates an "International Reliance" pathway, allowing manufacturers with approvals from trusted global regulators (like the US FDA) to fast-track their entrance into the UK market and bypass redundant testing. 2. Deep-Tech &amp; Interoperability FundingVenture capital and EU grants are favouring heavily vetted, clinical-grade innovations over lifestyle software.Smart Contact Lenses: Belgian healthtech firm Azalea Vision secured up to €7.5 million from the EU’s European Innovation Council (EIC) Accelerator program. The funding will advance their medical-grade smart contact lens, which treats complex vision issues and tracks biomarkers in tears—into clinical trials.Crushing Data Silos: The EIC announced the first winners of its health data interoperability initiative, deploying a combined €3.78 million to projects like CARDIO-HUB (remote heart monitoring for the elderly) and NEODATA+(neonatal intensive care data). The goal is a shift from isolated "pilot programs" to full-scale cross-border data deployment.AI Foundation Toxicology: A new Horizon Europe funding call via the Innovative Health Initiative (IHI) was introduced to back a collaborative consortium developing an AI Foundation Toxicology Model, aiming to use machine learning to safely consolidate pharmaceutical data and predict drug safety early on.3. Commercial Realities: From "Promise to Proof"Data from recent industry forums like HLTH Europe and the Philips Future Health Index highlight a major vibe shift among buyers:Workflow Automation is King: Roughly 65% of European clinicians have actively ramped up their use of AI medical tech, but primarily to claw back time from administrative duties.As a result, B2B software that tackles clinician burnout and optimizes hospital infrastructure (such as open, interoperable clinical platforms) is securing the lion's share of late-stage funding, while pure-play wellness apps are seeing a steep decline in institutional backing. The Emerging Risk: Legal experts warn that because formal "AI literacy" training requirements for doctors have been diluted in recent legislative drafts, manufacturers face a growing liability threat if a time-strapped clinician incorrectly interprets an AI diagnostic output.&gt;&gt;&gt;&gt;The European MedTech sector is undergoing an intense structural shift. While software-heavy HealthTech is moving toward workflow automation, physical medical hardware and devices (MedTech) are hitting massive regulatory and procurement bottlenecks, sparking significant updates and pushback this week.The defining MedTech developments shaping the European market include:1. Regulatory Overlap Crisis: The MDR vs. SoHO ClashThe single biggest headline in European medical hardware this week is a formal warning issued by a Council of Europe committee (the CD-P-TO).The Overlap: The committee warned that an "overly expansive" interpretation of the Medical Device Regulation (MDR) is directly threatening patient access to therapies based on human blood, tissues, and cells.The Conundrum: The new Substances of Human Origin (SoHO) legislation is set to fully apply by August 2027. Right now, manufacturers are panicking because they risk entering the post-2027 era simultaneously answerable to two distinct, overlapping regulatory regimes—complete with separate inspection frameworks and duplicate documentation.The Impact: Because low-volume, highly specialized medical devices are being withdrawn from the European market due to high MDR compliance costs, some health institutions are resorting to using "Research Use Only" (RUO) devices outside of their intended purposes just to maintain patient care. Industry groups are demanding immediate intervention from the European Commission to separate the two rules.2. In Vitro Diagnostics (IVD) Market AlarmFollowing the ongoing rollout of the In Vitro Diagnostics Regulation (IVDR), Europe's €13 billion IVD sector is sounding the alarm on a major supply chain bottleneck.The Problem: Paradoxically, while European Notified Bodies (the organizations that validate device safety) have recently cut staff due to a temporary slowdown in technical documentation submissions, the testing pipeline itself is incredibly fragile.The Pushback: MedTech Europe published an aggressive position paper welcoming some proposed EU revisions but demanding urgent tweaks to how the continent handles orphan diagnostics, risk classifications, and health institution tests. The sector warns that without a simplified, predictable, risk-based framework, European patients will lose access to critical lab diagnostics.3. Procurement Pivot: Recommending "Value Over Low Price"A major strategic shift is underway regarding how European hospitals purchase capital medical equipment and implantables.Ending Price-Only Tenders: Historically, European public healthcare systems have relied heavily on price-only procurement, which naturally favours cheaper imports and undercuts high-quality local hardware manufacturers.The New Framework: This week, industry leaders mobilized a massive push toward Value-Based Procurement.Citing frameworks co-developed with the Boston Consulting Group, trade bodies are pressuring EU member states to rewrite hospital bidding rules. The goal is to prioritize long-term clinical outcomes, risk-sharing agreements with suppliers, and supply chain resilience over the lowest sticker price. The Geopolitical Context: Midway through 2026, European hardware firms are facing severe macroeconomic headwinds compared to their US counterparts. Due to ongoing reciprocal trade tariffs on goods entering the US (Europe's primary export market), European MedTech manufacturers are leaning heavily on local EU grants—like the newly opened Innovative Health Initiative (IHI) Incubator Network calls—to fund early-stage hardware commercializationNelson Advisors &gt; European MedTech and HealthTech Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb</a>&nbsp;Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTlloyd@nelsonadvisors.co.ukpaul@nelsonadvisors.co.ukMeet Nelson Advisors @ 2026 EventsDigital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp;HLTH Europe &gt; June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp;World Health Summit 2026 &gt; October 2026, Berlin, GermanyHealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USABarclays Health Elevate &gt; October 2026, London, UK&nbsp;Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, GermanyVenture Capital World Summit &gt; December 2026 Toronto, Canada

Nelson Advisors

Blog

Nelson Advisors featured in Mergermarket's Dealspeak APAC

This Week in European MedTech and HealthTech: 17th July 2026

The Rise of the Founder Banker in European Healthcare Tec...

Nelson Advisors invited to speak at the Capital XChange P...

Nelson Advisors featured in InnLifes article 'Come è nata...

This Week in European MedTech and HealthTech: 10th July 2026